Company intelligence / Profile preview

Antiger Therapeutics

Saint Louis, Missouri, United Statessbir.gov ↗

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Antiger Therapeutics is developing biologic therapies that target immune responses in celiac disease by blocking pathogenic T cells recognizing gluten peptide-HLA-DQ2 complexes. The company is also advancing HLA-based biologics to prevent antibody-mediated graft rejection in transplant recipients. As of 2025, the company has received SBIR Phase I funding but has not reported clinical results or advanced programs beyond early preclinical/Phase I stages

Therapeutic areas: GastroenterologyImmunology
Modalities: BiologicRecombinant proteinPeptides (specifically peptide-HLA complexes)
Industry: Biotech

Partnerships

St. Louis Inno Madness competition/investor support noted, but no major pharma/biotech partnerships disclosed as of June 2025

Beyond the preview

Go deeper on Antiger Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antiger Therapeutics.

Explore the full profile